Results 131 to 140 of about 196,164 (338)

Patients with infusion-related reactions on fixed-dose rituximab treatment have higher body surface area than those without infusion-related reactions in adults with frequently relapsing minimal change nephrotic syndrome: a retrospective study

Journal of Pharmaceutical Health Care and Sciences
Background Infusion-related reactions (IRRs) are major side effects of rituximab administration. Male sex, high body weight, body surface area (BSA), and body mass index are predictive markers of rituximab-induced IRRs.
Hironobu Nishiura, Masaya Takahashi, Katsuhito Mori, Takashi Sugimoto, Masanori Emoto, Yasutaka Nakamura   +5 more
doaj   +1 more source

LOTIS‐5, AN ONGOING PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE WITH RITUXIMAB (LONCA‐R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL [PDF]

, 2023
Carmelo Carlo‐Stella, M. Kwiatek, Michael Chung, Heidi Móciková, Juan-Miguel Bergua‐Burgues, Sujun Gao, Sebastian Grosicki, Anastasios Stathis, Dominique Toupin, Yan Wang, L. Wang, Mehdi Hamadani   +11 more
openalex   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

Arthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman, Voon Ong, Christopher P. Denton   +2 more
wiley   +1 more source

Assessment of Efficacy of Adjuvant Topical Rituximab Encapsulated in Nanoparticle Gel in Oral Pemphigus Vulgaris: A Randomized, Double-Blind, Placebo-Controlled, Pilot Study

Indian Dermatology Online Journal
Background: Oral pemphigus vulgaris (PV) presents with persistent, painful, nonhealing oral erosions, with a slower treatment response compared to cutaneous lesions.
Pratik Rajendra Mohta, Sujay Khandpur, Amit Kumar Dinda, Madhusudan Bhat, Seema Tyagi, Vinod Kumar Sharma, Mani Kalaivani   +6 more
doaj   +1 more source

Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial

Arthritis &Rheumatology, EarlyView.
Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih, Shiow‐Ing Wang, Qing‐Wen Wang, James Cheng Chung Wei   +3 more
wiley   +1 more source

Should tocilizumab be the first line treatment for neuromyelitis optica together with rituximab?

, 2021
Raja Sawaya, G. Saab, Hussein Moussa
openalex   +1 more source

Neutralizing monoclonal antibodies against SARS-CoV-2 for COVID-19 pneumonia in a rituximab treated patient with systemic sclerosis—A case report and literature review [PDF]

, 2022
Melek Yalçın Mutlu, Jule Taubmann, Jochen Wacker, Koray Taşçılar, Filippo Fagni, Maximilian Gerner, Daniel Klett, Georg Schett, Bernhard Manger, David Simón   +9 more
openalex   +1 more source

A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis

Arthritis &Rheumatology, Accepted Article.
Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane, Christopher C. Striebich, Marie L. Feser, James R. O'Dell, Judith A. James, Jeffrey A. Sparks, John M. Davis, Jonathan Graf, Maureen A. McMahon, Elizabeth B. Solow, Lindsy Forbess, Athan Tiliakos, Elena Schiopu, Maria I. Danila, Diane L. Horowitz, Jonathan Kay, Colin D. Strickland, Joel M. Guthridge, Cristina Arriens, Jennifer M. Grossman, M. Kristen Demoruelle, Elizabeth A. Bemis, Ashley Frazer‐Abel, Chelsie L. Fleischer, David A. Fox, Ted R. Mikuls, Melissa Greenleaf, Kate York, Sarah Walker, Lynette Keyes‐Elstein, Margie Byron, Janel Fedler, Ellen A. Goldmuntz, V. Michael Holers   +33 more
wiley   +1 more source

Plasmapheresis for Facilitating Readministration of Rituximab After Paradoxical Exacerbation in Pemphigus Vulgaris: A Case Report

Clinical Case Reports
Rare reports of post‐rituximab exacerbation of pemphigus vulgaris (PV) have been published, with some therapeutic protocols proposed for managing this condition.
Mohammad Reza Pourani, Sayyed Mojtaba Nekooghadam, Fatemeh Samadi, Sanaz Soleimani, Fahimeh Abdollahimajd   +4 more
doaj   +1 more source

Cytokine pathways driving diverse tissue pathologies in rheumatoid arthritis

Arthritis &Rheumatology, Accepted Article.
Rheumatoid arthritis is a complex systemic disorder characterised primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease e.g. of the lung with potentially devastating clinical consequences.
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source